What is claimed:

1. A composition comprising:
   a) about 1 mg to about 50 mg of a polypeptide comprising a circularly permuted IL-2 fused to the extracellular portion of an IL-2Rα chain;
   b) sucrose;
   c) citrate buffer; and
   d) polysorbate 20.

2. The composition of claim 1, wherein the polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1.

3. The composition of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

4. The composition of any one of claims 1-3, wherein the composition comprises about 2.2 mg of the polypeptide.

5. The composition of any one of claims 1-3, wherein the composition comprises about 11 mg of the polypeptide.

6. The composition of any one of claims 1-3, wherein the composition comprises about 33 mg of the polypeptide.

7. The composition of any one of the preceding claims, wherein the composition comprises about 100 mg to about 120 mg sucrose.

8. The composition of any one of the preceding claims, wherein the composition comprises about 110 mg sucrose.

9. The composition of any one of the preceding claims, wherein the composition comprises about 4.0 mg to about 6.0 mg of citrate anion.

10. The composition of any one of the preceding claims, wherein the composition comprises about 5.0 mg citrate anion.

11. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of between about 1:10 to about 1:2.

12. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of about 1:9.

13. The composition of any one of the preceding claims, wherein the composition comprises citric acid and sodium citrate tribasic dihydrate in a mass ratio of citric acid:sodium citrate tribasic dihydrate of about 1:2.

14. The composition of any one of the preceding claims, wherein the composition comprises about 0.20 mg to about 0.24 mg polysorbate 20.

15. The composition of any one of the preceding claims, wherein the composition comprises about 0.22 mg polysorbate 20.

16. The composition of any one of the preceding claims, wherein the composition is a lyophilized cake.

17. The composition of claim 16, wherein dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 5.5 to about 6.5.

18. The composition of claim 17, wherein dissolution of the lyophilized cake in water results in an aqueous solution with a pH of about 6.1.

19. The composition of any one of claims 16-18, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 160 to about 230 mOsm/kg.

20. The composition of claim 19, wherein dissolution of the lyophilized cake in water results in an aqueous solution with an osmolality of about 179 mOsm/kg.

21. The composition of any one of claims 16-18, wherein dissolution of the lyophilized cake in a sodium chloride solution results in an aqueous solution with an osmolality of about 240 to about 340 mOsm/kg.

22. The composition of claim 21, wherein the sodium chloride solution comprises about 0.1% NaCl to about 0.5% NaCl.

23. The composition of claim 21, wherein the sodium chloride solution comprises about 0.12% NaCl to about 0.41% NaCl.

24. The composition of claim 21, wherein the sodium chloride solution comprises about 0.02 M NaCl to about 0.07 M NaCl.

25. The composition of any one of claims 1-15, wherein the composition is an aqueous solution.

26. The composition of claim 25, wherein the composition comprises about 1 mg/mL of the polypeptide.

27. The composition of claim 26, wherein the composition is a 2.2 ml aqueous solution comprising about 2.2 mg of the polypeptide.

28. The composition of claim 25, wherein the composition comprises about 5 mg/mL of the polypeptide.

29. The composition of claim 28, wherein the composition is a 2.2 ml aqueous solution comprising about 11 mg of the polypeptide.

30. The composition of claim 25, wherein the composition comprises about 15 mg/mL of the polypeptide.

31. The composition of claim 30, wherein the composition is a 2.2 ml aqueous solution comprising about 33 mg of the polypeptide.

32. The composition of any one of claims 25-31, wherein the composition comprises about 45 mg/mL to about 55 mg/mL sucrose.

33. The composition of claim 32, wherein the composition comprises about 50 mg/mL sucrose.

34. The composition of any one of claims 25-33, wherein the composition comprises about 10 mM to about 20 mM citrate buffer.

35. The composition of claim 34, wherein the composition comprises about 12 mM citrate buffer.

36. The composition of any one of claims 25-35, wherein the citrate buffer is formed by the combination of 2.03 mg/mL sodium citrate tribasic dihydrate and 0.97 mg/mL citric acid monohydrate in the aqueous solution.

37. The composition of any one of claims 25-36, wherein the composition comprises about 0.09 mg/mL to about 0.11 mg/mL polysorbate 20.

38. The composition of claim 37, wherein the composition comprises about 0.1 mg/mL polysorbate 20.

39. The composition of any one of claims 25-38, wherein the pH of the composition is about 5.5 to about 6.5.

40. The composition of claim 36, wherein the pH of the composition is about 6.1.

41. The composition of any one of claims 25-40, wherein the osmolality of the composition is about 160 to about 230 mOsm/kg.

42. The composition of claim 41, wherein the osmolality of the composition is about 179 mOsm/kg.

43. The composition of any one of claims 25-42, wherein the aqueous solution comprises about 0.03 mg/mL of the polypeptide to about 0.2 mg/mL of the polypeptide.

44. A lyophilized composition made by lyophilizing the composition of any one of claims 25-44.

45. The composition of any one of the preceding claims, wherein the composition is a single unit dose of the polypeptide.

46. An article of manufacture comprising the composition of any one of the preceding claims.

47. The article of manufacture of claim 46, which is a glass vial.

48. A method of making a lyophilized composition, the method comprising lyophilizing the aqueous solution of any one of claims 25-43.

49. A method of making an aqueous composition, the method comprising dissolving the composition of claim 16 or 44 in an aqueous solvent.

50. The method of claim 49, wherein the aqueous solvent comprises water for injection.

51. The method of claim 49, wherein the aqueous solvent comprises a sodium chloride solution.

52. The method of claim 51, wherein the sodium chloride solution comprises about 0.1% NaCl to about 0.5% NaCl.

53. The method of claim 51, wherein the sodium chloride solution comprises about 0.12% NaCl to about 0.41% NaCl.

54. The method of claim 51, wherein the sodium chloride solution comprises about 0.02 M NaCl to about 0.07 M NaCl.

55. The method of any one of claims 51-54, wherein aqueous composition comprises an osmolality of about 240 to about 340 mOsm/kg.

56. The method of any one of claims 49-55, wherein the pH of the aqueous composition is adjusted to about 6.1.

57. The method of any one of claims 49-56, wherein the pH of the aqueous composition is adjusted to about 6.1 with a base.

58. The method of claim 57, wherein the base is sodium hydroxide.

59. The method of any one of claims 49-58, wherein the aqueous composition is further diluted with an aqueous solution comprising about 1% (w/w) of a surfactant.

60. The method of claim 59, wherein the surfactant is polysorbate 20.

61. The method of claim 59, wherein the aqueous solution further comprises about 0.1% (w/w) citric acid monohydrate, 0.2% (w/w) sodium citrate tribasic dihydrate, and 98.7% (w/w) water for injection.

62. A method of activating natural killer cells (NK) cells in a subject, the method comprising administering to the subject an effective amount of the composition of any one of claims 25-43.

63. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of any one of claims 25-43.

64. The method of claim 63, wherein the cancer is renal cell carcinoma, melanoma, ovarian cancer, or lung cancer.

65. The method of claim 63 or 64, wherein the cancer comprises a refractory solid tumor.